Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a group of antidiabetic medications with a favourable cardiovascular, renal and overall safety profile. Given the limited treatment options available for neurological disorders, it is important to determine whether the pleiotropic ef...
Saved in:
Main Authors: | Thahesh Tharmaraja (Author), Jamie S.Y. Ho (Author), Ching-Hui Sia (Author), Nicole-Ann Lim (Author), Yao Feng Chong (Author), Amanda Y.L. Lim (Author), Rahul R. Rathakrishnan (Author), Leonard L.L. Yeo (Author), Vijay K. Sharma (Author), Benjamin Y.Q. Tan (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022) -
Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018) -
Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
by: Alicia Swee Yan Yip, et al.
Published: (2022) -
Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023) -
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020)